Publications by authors named "Trinh T T Tran"
Article Synopsis
- Tyrosine kinase inhibitors (TKIs) are the main treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, but resistance to these drugs often develops due to new mutations and they can cause severe side effects.
- Researchers are exploring customized antisense oligonucleotides (ASOs) to specifically target these mutations, using extracellular vesicles to deliver them directly to cancer cells.
- Preliminary results show that ASOs can effectively reduce tumor growth in models of NSCLC and may work better than TKIs, offering a promising new treatment approach tailored to individual genetic profiles.
Nanoparticles (NPs) hold great potential as therapeutics, particularly in the realm of drug delivery. They are effective at functional cargo delivery and offer a great degree of amenability that can be used to offset toxic side effects or to target drugs to specific regions in the body. However, there are many challenges associated with the development of NP-based drug formulations that hamper their successful clinical translation.
View Article and Find Full Text PDFEctonucleotide pyrophosphate phosphodiesterase type II (ENPP2), also known as Autotaxin (ATX), is an enzyme present in blood circulation that converts lysophosphatidyl choline (LPC) to lysophosphatidic acid (LPA). While LPA has been demonstrated to play diverse roles in skeletal myogenesis, mainly through in vitro studies, the role of ENPP2 in skeletal myogenesis has not been determined. We previously found that Enpp2 is induced by a positive WNT/β-Catenin signaling regulator, R-spondin2 (RSPO2), in C2C12 myoblast cells.
View Article and Find Full Text PDF